CGEN

#3025
Compugen Ltd. - Ordinary Shares
2.6 3 USD
-5.40%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
2.63
2.63
Yıllık Aralık
1.32
3.24
Günlük Değişim
-5.40%
Aylık Değişim
+0.38%
6 Aylık Değişim
+67.52%
Yıllık Değişim
+69.68%
Önceki Kapanış
2.7 8
Open
2.6 3
Düşük
2.6 3
High
2.6 3
Hacim
11
Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler
Çeyreklik Yıllık
  • Market Capitalization 248.67 M
  • Employee 75
  • Founded 1993
  • CEO Anat Cohen-Dayag
  • Website www.cgen.com
  • Headquarter Israel
  • FIGI UNKNOWN
  • Industry Biyoteknoloji
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
4.03
Fiyat/satışlar oranı
1.97

Compugen Ltd. - Ordinary Shares

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

Haberler